24/7 Market News Snapshot 16 January, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)

January 16, 2025

DENVER, Colo., 16 January, 2025 (247marketnews.com) – (NASDAQ:PALI) are discussed in this article.
Palisade Bio, Inc. is witnessing a significant upward trend in the pre-market session, with its stock price climbing to $1.883, reflecting a robust increase of 6.99% from the previous close of $1.760. This rise demonstrates strong investor interest, highlighted by an impressive trading volume of 7.94 million shares. Such activity may indicate a positive market sentiment or recent news catalysts fostering demand. Analysts suggest that the stock’s upward momentum, coupled with this increase in volume, could point to a potential continuation of this positive trend, prompting investors to closely monitor key resistance and support levels for making informed trading decisions.

In parallel, Palisade Bio has achieved a crucial milestone in its clinical efforts, having successfully completed all five Single Ascending Dose (SAD) cohorts in its Phase 1a/b study for PALI-2108, aimed at treating Ulcerative Colitis (UC). The data gathered indicates that PALI-2108 is well-tolerated across a wide dosage range from 15 mg to 450 mg, with no serious adverse events reported. While mild treatment-emergent adverse events were primarily associated with the highest dosage, these findings reinforce the favorable safety profile of the investigational drug.

Pharmacokinetic analyses have showcased PALI-2108’s promising delayed and extended-release properties, resulting in sustained, dose-dependent exposure and elevated local concentrations within the colon—crucial for effectively targeting UC. With these encouraging results, Palisade Bio is poised to transition into the Multiple Ascending Dose (MAD) phase, aimed at further establishing the safety and pharmacokinetics of PALI-2108 in both healthy volunteers and UC patients.

Palisade Bio’s Chief Medical Officer, Dr. Mitch Jones, expressed optimism about the recent progress and the impending transition to the MAD phase, emphasizing the company’s commitment to providing innovative treatment options for UC patients. Topline data from this next phase is anticipated in the first half of 2025, reinforcing Palisade Bio’s dedication to advancing therapeutic alternatives in the biopharmaceutical landscape.

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.